Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: The phase 3 randomized SUNLIGHT study.

被引：0
|
作者：
Tabernero, Josep
Prager, Gerald W.
Fakih, Marwan
Ciardiello, Fortunato
Van Cutsem, Eric
Elez, Elena
Cruz, Felipe Melo
Wyrwicz, Lucjan
Stroyakovskiy, Daniil
Papai, Zsuzsanna
Poureau, Pierre-Guillaume
Liposits, Gabor
Cremolini, Chiara
Bondarenko, Igor
Modest, Dominik Paul
Benhadji, Karim A.
Fougeray, Ronan
Leger, Catherine
Amellal, Nadia
Taieb, Julien
机构：
[1] Vall dHebron Hosp Campus, Barcelona, Spain
[2] UVic UCC, Inst Oncol VHIO, IOB Quiron, Barcelona, Spain
[3] Med Univ Vienna, Vienna, Austria
[4] City Hope Natl Comprehens Canc Ctr, Duarte, CA USA
[5] Univ Campania Luigi Vanvitelli, Precis Med Dept, Naples, Italy
[6] Univ Hosp Gasthuisberg Leuven, Dept Digest Oncol, Herent, Belgium
[7] Katholieke Univ Leuven, Herent, Belgium
[8] Vall dHebron Univ Hosp, Barcelona, Spain
[9] UVic UCC, Vall dHebron Inst Oncol VHIO, Barcelona, Spain
[10] Nucleo Pesquisa & Ensino Rede Sao Camilo, Sao Paulo, Brazil
[11] Maria Sklodowska Curie Natl Canc Res Inst, Dept Radiotherapy & Oncol, Warsaw, Poland
[12] Moscow City Oncol Hosp 62, Moscow Area, Russia
[13] Duna Med Ctr, Med Oncol, Budapest, Hungary
[14] Inst Cancerol, Brest, France
[15] Univ Southern Denmark, Dept Clin Res, Odense, Denmark
[16] Univ Pisa, Dept Translat Res & New Technol, Pisa, Italy
[17] Dnipropetrovsk Med Acad, Dept Oncol & Med Radiol, Dnipro, Ukraine
[18] Charite Univ Med Berlin, Berlin, Bagun, Germany
[19] Taiho Oncol Inc, Princeton, NJ USA
[20] Servier Int Res Inst, Suresnes, France
[21] Univ Paris Cite Paris Descartes, Pompidou European Hosp, SIRIC CARPEM, Paris, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4
引用
收藏
页码：4 / 4
页数：1
相关论文
共 50 条
  • [1] Trifluridine/tipiracil plus bevacizumab for third-line treatment of refractory metastatic colorectal cancer: the phase 3 randomized SUNLIGHT study
    Modest, D. P.
    Tabernero, J.
    Prager, G.
    Fakih, M.
    Ciardiello, F.
    Van Cutsem, E.
    Elez, E.
    Cruz, F.
    Wyrwicz, L.
    Stroyakovskiy, D.
    Papai, Z.
    Poureau, P. -G.
    Liposits, G.
    Cremolini, C.
    Benhadji, K.
    Bondarenko, I.
    Skanji, D.
    Roby, L.
    Amellal, N.
    Taieb, J.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 157 - 158
  • [2] Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design
    Tabernero, Josep
    Taieb, Julien
    Prager, Gerald W.
    Ciardiello, Fortunato
    Fakih, Marwan
    Leger, Catherine
    Fougeray, Ronan
    Amellal, Nadia
    van Cutsem, Eric
    [J]. FUTURE ONCOLOGY, 2021, 17 (16) : 1977 - 1985
  • [3] Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy
    Giuliani, Jacopo
    Mantoan, Beatrice
    Mangiola, Daniela
    Muraro, Marco
    Napoli, Giuseppe
    Tommasi, Marina
    Fiorica, Francesco
    Mandara, Marta
    [J]. CLINICAL COLORECTAL CANCER, 2024, 23 (01) : 1 - 3
  • [4] Plain language summary of SUNLIGHT: trifluridine/tipiracil and bevacizumab for refractory metastatic colorectal cancer
    Prager, Gerald W.
    Taieb, Julien
    Fakih, Marwan
    Ciardiello, Fortunato
    Cutsem, Eric Van
    Elez, Elena
    Wyrwicz, Lucjan
    Stroyakovskiy, Daniil
    Liposits, Gabor
    Bondarenko, Igor
    Modest, Dominik P.
    Amellal, Nadia
    Tabernero, Josep
    [J]. FUTURE ONCOLOGY, 2024,
  • [5] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: A retrospective study
    Li, Rongrong
    Zhou, Hui-Jun
    Zeng, De-Yu
    Jiang, Shao-Feng
    Liu, Wu
    Liu, Zhen-yang
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer
    Prager, Gerald W.
    Taieb, Julien
    Fakih, Marwan
    Ciardiello, Fortunato
    Van Cutsem, Eric
    Elez, Elena
    Cruz, Felipe M.
    Wyrwicz, Lucjan
    Stroyakovskiy, Daniil
    Papai, Zsuzsanna
    Poureau, Pierre-Guillaume
    Liposits, Gabor
    Cremolini, Chiara
    Bondarenko, Igor
    Modest, Dominik P.
    Benhadji, Karim A.
    Amellal, Nadia
    Leger, Catherine
    Vidot, Loick
    Tabernero, Josep
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (18): : 1657 - 1667
  • [7] A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer
    Moehler, Markus
    Michel, Maurice
    Stein, Alexander
    Trojan, Joerg
    Marquardt, Jens
    Tintelnot, Joseph
    Waidmann, Oliver
    Weinmann, Arndt
    Woerns, Marcus-Alexander
    Schroeder, Helge
    Maenz, Martin
    Foerster, Friedrich
    [J]. FUTURE ONCOLOGY, 2021, 17 (25) : 3309 - 3319
  • [8] Retrospective study of regorafenib and trifluridine/tipiracil efficacy as a third-line or later chemotherapy regimen for refractory metastatic colorectal cancer
    Tanaka, Akira
    Sadahiro, Sotaro
    Suzuki, Toshiyuki
    Okada, Kazutake
    Saito, Gota
    Miyakita, Hiroshi
    [J]. ONCOLOGY LETTERS, 2018, 16 (05) : 6589 - 6597
  • [9] The TRUSTY Study: A Randomized Phase 2/3 Study of Trifluridine/Tipiracil Plus Bevacizumab Versus Irinotecan and Fluoropyrimidine Plus Bevacizumab as Second-Line Treatment in Patients With Metastatic Colorectal Cancer
    不详
    [J]. CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2021, 19 (09) : 9 - 10
  • [10] Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study
    Li, Rong-Rong
    Zhou, Hui-Jun
    Zeng, De-Yu
    Jiang, Shao-Feng
    Liu, Wu
    Fruehling, Petter
    Liu, Zhen-Yang
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2024, 15 (02) : 612 - 629
12345